Neurotech International Limited (ASX:NTI)
Australia · Delayed Price · Currency is AUD 0.0140
+0.0015 (12.00%)
Sep 18, 2026, 2:50 PM AEST
Neurotech International Revenue
In the fiscal year ending June 30, 2026, Neurotech International had annual revenue of 4.73M AUD with 93.68% growth. Neurotech International had revenue of -7.10K in the half year ending June 30, 2026.
Revenue
4.73M
Revenue Growth
+93.68%
P/S Ratio
3.49
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 4.73M | 2.29M | 93.68% |
| Jun 30, 2025 | 2.44M | -732.95K | -23.07% |
| Jun 30, 2024 | 3.18M | 1.98M | 166.00% |
| Jun 30, 2023 | 1.19M | 586.87K | 96.59% |
| Jun 30, 2022 | 607.62K | 401.25K | 194.44% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| NeuroScientific Biopharmaceuticals | 402.66K |